Jim Cramer's top 10 things to watch in the stock market Tuesday

The 10-year Treasury yield briefly reached 5.04%, its highest level since 2007, while WTI crude remained above $102 per barrel ahead of a Fed decision for which markets assign a greater than 92% probability of a 25bp rate hike. Company-specific moves were mixed: Corning fell 13.7% after a $2 billion equity sale, Dave & Buster's dropped more than 13% premarket following an earnings miss, while Eli Lilly and Etsy received upgrades implying roughly 23% and 21% upside, respectively. Dominion and NextEra also increased proposed consumer benefits in their planned $67 billion utility merger, offering $10 monthly residential bill credits for four years.

Analysis

The dominant cross-asset mechanism is duration compression: a sustained 5%+ long-end yield raises the equity-risk premium hurdle most sharply for high-multiple AI infrastructure, software and regulated utilities. NVDA, GLW and NEE/D should therefore be judged less on near-term narrative momentum than on whether earnings revisions can outpace the discount-rate shock; absent that, multiple compression can overwhelm intact fundamentals over the next 1-3 months. The near-term Fed outcome matters less than the terminal-rate and long-run-growth projections that determine whether the long end remains elevated.

Cybersecurity is comparatively insulated because AI expands the attack surface faster than enterprise security budgets can be deferred. PANW offers the more defensive expression versus CRWD if rate volatility persists: its broader platform/cross-sell model and lower duration profile should hold up better if customers consolidate vendors, while CRWD retains greater upside if security spending reaccelerates. The key falsifier is evidence in October-quarter results that net-new ARR, module adoption or billings are slowing materially rather than merely subject to procurement timing.

GLW's financing action should be treated as a balance-sheet signal, not automatically a valuation opportunity. Equity-funded capacity or working-capital needs reduce downside liquidity risk but also imply that incremental AI-optics revenue may not self-fund the investment cycle; this raises the bar for returns on capital and creates an overhang until deployment economics are disclosed. Conversely, PLAY's earnings miss is more consequential than a typical consumer discretionary reset because leveraged balance sheets convert modest traffic or pricing errors into disproportionate equity downside.

The consensus may be too quick to extrapolate an analyst upgrade into a durable ETSY turnaround. AI-search improvements can lower paid-acquisition dependence, but the economically relevant proof is repeat-buyer frequency and take-rate stability; without those, better conversion may simply subsidize seller competition. LLY remains a structural winner, but after a positive research note the more attractive risk/reward is to wait for a broad biotech or rates-driven pullback rather than chase a target-price catalyst.

Key Decisions for Investors

• Maintain an underweight in long-duration AI infrastructure for the next 1-3 months; use NVDA rallies into Fed/long-yield volatility to trim rather than add unless the 10-year yield decisively retraces below 4.75% or consensus EPS estimates rise enough to offset valuation compression.
• Initiate a 3-6 month long PANW / short CRWD pair in equal beta-adjusted dollars. The thesis is vendor consolidation and lower rate sensitivity; exit if CRWD billings/ARR acceleration materially exceeds PANW next-quarter RPO or billings growth, or if the 10-year yield falls below 4.6%, which would favor CRWD's higher-duration multiple.
• Avoid GLW until management quantifies proceeds use, incremental capacity returns and any change in AI-related revenue timing. Consider a tactical long only after the financing overhang clears and the stock stabilizes above the post-offering low; otherwise, weak data-center capex commentary would make GLW a short candidate versus a diversified semiconductor-infrastructure basket.
• Short PLAY or buy 3-6 month put spreads on a failed post-earnings bounce, targeting a further 10-15% downside if comparable-sales weakness persists. Keep position size modest: the principal squeeze risk is a strategic/asset-value bid or a sharp consumer-spending rebound; cover on demonstrable traffic recovery and leverage-reduction guidance.
• Place LLY on a buy-on-drawdown list rather than chase. Add on a 8-12% market-driven pullback with 12-18 month horizon, but reassess if obesity-drug supply expansion fails to translate into volume growth or if non-obesity pipeline spending begins diluting return-on-invested-capital expectations.